<?xml version="1.0" encoding="UTF-8"?>
<p id="p0200">The dose of favipiravir used to treat a human with an Ebola virus infection is 6000 mg on the first day and 2400 mg/day on days 1–9 for a total of 27,600 mg when administered for both PEP and treatment. Four of eight health-care workers, including two with maximum risk exposures from penetrating injuries with freshly used hollow-bore needles, were administered PEP with favipiravir alone or favipiravir with other anti-Ebola agents and did not develop Ebola virus disease (
 <xref rid="bb0265" ref-type="bibr">Jacobs et al., 2015</xref>). Although the needle stick had not been confirmed to result in infection, the probability of infection was high based on previous observations, and PEP was considered effective, as observed in PEP using a mouse model (
 <xref rid="bb0550" ref-type="bibr">Smither et al., 2014</xref>).
</p>
